Literature DB >> 17273155

Hypertension and fatty liver: guilty by association?

M J Brookes1, B T Cooper.   

Abstract

Essential hypertension is associated with the metabolic syndrome, insulin resistance and the development of fatty liver. Fatty liver disease is a spectrum of liver diseases ranging from simple hepatic steatosis through steato-hepatitis to cirrhosis and hepatoma. The purpose of this review is to discuss the evidence for an association between essential hypertension and non-alcoholic fatty liver disease, and to consider the diagnosis and management of non-alcoholic fatty liver disease. We conclude that it is important to consider the diagnosis of fatty liver disease in hypertensive patients, to measure the liver function tests at diagnosis and not to ignore minor elevations of serum aminotransferases. Hypertensive patients with raised liver enzymes should be referred for further assessment, particularly if risk factors for progressive liver disease, such as obesity and diabetes, are present.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17273155     DOI: 10.1038/sj.jhh.1002148

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  18 in total

1.  Selection of reference genes for qRT-PCR in high fat diet-induced hepatic steatosis mice model.

Authors:  Lingyan Xu; Xinran Ma; Bin Cui; Xiaoying Li; Guang Ning; Shu Wang
Journal:  Mol Biotechnol       Date:  2011-07       Impact factor: 2.695

2.  Obesity-induced hepatic steatosis is mediated by endoplasmic reticulum stress in the subfornical organ of the brain.

Authors:  Julie A Horwath; Chansol Hurr; Scott D Butler; Mallikarjun Guruju; Martin D Cassell; Allyn L Mark; Robin L Davisson; Colin N Young
Journal:  JCI Insight       Date:  2017-04-20

Review 3.  Hypertension Induced Morphological and Physiological Changes in Cells of the Arterial Wall.

Authors:  Patricia Martinez-Quinones; Cameron G McCarthy; Stephanie W Watts; Nicole S Klee; Amel Komic; Fabiano B Calmasini; Fernanda Priviero; Alexander Warner; Yu Chenghao; Camilla F Wenceslau
Journal:  Am J Hypertens       Date:  2018-09-11       Impact factor: 2.689

4.  The HAALT Non-invasive Scoring System for NAFLD in Obesity.

Authors:  Harsh Sheth; Samir Bagasrawala; Mita Shah; Rais Ansari; A Olithselvan; Muffazal Lakdawala
Journal:  Obes Surg       Date:  2019-08       Impact factor: 4.129

5.  Effects of primary hypertension treatment in the oncological outcomes of hepatocellular carcinoma.

Authors:  Victor Lopez-Lopez; Alvaro Gomez Ruiz; Asunción Lopez-Conesa; Roberto Brusadin; Valentin Cayuela; Albert Caballero-Illanes; Máximo Torres; Ricardo Robles Campos
Journal:  Ann Transl Med       Date:  2020-07

Review 6.  Hypertension and hepatic steatosis.

Authors:  Matthew J Brookes; Tariq H Iqbal; Brian T Cooper
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

7.  Cleavage and reduced CD36 ectodomain density on heart and spleen macrophages in the spontaneously hypertensive rat.

Authors:  Marco H Santamaria; Angela Y Chen; Jason Chow; Diana C Muñoz; Geert W Schmid-Schönbein
Journal:  Microvasc Res       Date:  2014-08-27       Impact factor: 3.514

8.  Association between non-alcoholic hepatic steatosis and hyper reactive blood pressure response on the exercise treadmill test.

Authors:  A G Laurinavicius; M S Bittencourt; M J Blaha; F C Nary; N M Kashiwagi; R D Conceiçao; R S Meneghelo; R R Prado; J A M Carvalho; K Nasir; R S Blumenthal; R D Santos
Journal:  QJM       Date:  2016-01-19

9.  Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats.

Authors:  Yongzhong Wei; Suzanne E Clark; John P Thyfault; Grace M E Uptergrove; Wenhan Li; Adam T Whaley-Connell; Carlos M Ferrario; James R Sowers; Jamal A Ibdah
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

10.  Carvacrol Protects against Hepatic Steatosis in Mice Fed a High-Fat Diet by Enhancing SIRT1-AMPK Signaling.

Authors:  Eunkyung Kim; Youngshim Choi; Jihee Jang; Taesun Park
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-20       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.